This company listing is no longer active
De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Acerus Pharmaceuticals Balans Gezondheid
Financiële gezondheid criteriumcontroles 0/6
Belangrijke informatie
-329.8%
Verhouding schuld/eigen vermogen
US$45.82m
Schuld
| Rente dekkingsratio | n/a |
| Contant | US$3.02m |
| Aandelen | -US$13.89m |
| Totaal verplichtingen | US$61.57m |
| Totaal activa | US$47.67m |
Recente financiële gezondheidsupdates
Recent updates
Auditors Have Doubts About Acerus Pharmaceuticals (TSE:ASP)
Mar 14
Have Insiders Been Buying Acerus Pharmaceuticals Corporation (TSE:ASP) Shares?
Mar 12Acerus Pharmaceuticals' (TSE:ASP) Shareholders Are Down 88% On Their Shares
Jan 22The Independent Director of Acerus Pharmaceuticals Corporation (TSE:ASP), Stephen Gregory, Just Bought 52% More Shares
Nov 30
Analyse van de financiële positie
Kortlopende schulden: ASP has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.
Langlopende schulden: ASP has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.
Schuld/ eigen vermogen geschiedenis en analyse
Schuldniveau: ASP has negative shareholder equity, which is a more serious situation than a high debt level.
Schuld verminderen: ASP's has negative shareholder equity, so we do not need to check if its debt has reduced over time.
Balans
Analyse van de cashflow
Voor bedrijven die in het verleden gemiddeld verliesgevend zijn geweest, beoordelen we of ze ten minste 1 jaar kasstroom hebben.
Stabiele cash runway: ASP has less than a year of cash runway based on its current free cash flow.
Voorspelling contante baan: ASP has less than a year of cash runway if free cash flow continues to reduce at historical rates of 45.6% each year